Paris - Hôpital Cochin
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The cardiology service at Hôpital Cochin is evaluating innovative catheter‑based strategies to improve outcomes for patients with coronary artery disease and high bleeding risk. Trials aim to compare newer device technologies and shorten antiplatelet therapy.
- Percutaneous coronary intervention with drug‑coated balloon versus drug‑eluting stent
- Management of stable coronary artery disease in anticoagulated patients
- Assessment of bleeding risk reduction strategies
These studies support personalized interventional approaches and may influence future guidelines for cardiac care in France.
Male Urogenital Diseases
Research on non‑seminomatous germ‑cell tumors focuses on young adults with poor‑prognosis disease, testing personalized marker‑driven treatment plans to enhance survival.
- Prospective validation of early tumor‑marker kinetics
- Tailored chemotherapy regimens for disseminated germ‑cell disease
- Safety monitoring of personalized protocols
The program, conducted at the Cochin oncology‑urology interface, seeks to set new standards for male reproductive cancer management.
Neoplasms
A broad oncology portfolio addresses solid tumours such as advanced non‑small cell lung cancer, metastatic kidney cancer, and sarcomas, with trials investigating immune checkpoint inhibitors, targeted agents, and molecularly guided therapies.
- Pembrolizumab plus cabozantinib in advanced sarcoma subtypes
- Adjuvant chemotherapy guided by a 14‑gene prognostic assay for resected NSCLC
- Nivolumab‑based combinations stratified by renal cell carcinoma molecular groups
- Oral fecal microbiotherapy with cemiplimab for checkpoint‑inhibitor‑resistant NSCLC
These investigations aim to improve response rates and personalize treatment across diverse cancer types.
Respiratory Tract Diseases
Clinical work in lung disease includes studies on metastatic non‑small cell lung cancer and the prevention of second primary cancers after curative therapy, evaluating immunotherapy and vaccine strategies.
- Efficacy of pembrolizumab‑cabozantinib in advanced NSCLC
- Dostarlimab as adjuvant therapy to reduce second primary cancer risk
- Biomarker‑driven adjuvant trials for early‑stage NSCLC
The site’s multidisciplinary team integrates pulmonology and oncology to accelerate advances in lung health.
Skin and Connective Tissue Diseases
Investigations into moderate‑to‑severe hidradenitis suppurativa test novel oral agents to determine optimal dosing and safety, aiming to expand therapeutic options for this chronic inflammatory condition.
- Dose‑finding study of LAD191
- Safety assessment of multiple dosing regimens
- Evaluation of disease‑control rate at 12 weeks
Outcomes may lead to new approved medications for patients with refractory skin disease.
Miscellaneous Research
Additional projects explore secondary prevention of HPV-related high‑grade squamous intra‑epithelial lesions using a nonavalent vaccine, targeting gynecological and anal sites to lower recurrence risk.
- HPV vaccination as secondary prevention
- Assessment of vaccine efficacy in cured HSIL patients
- Long‑term monitoring for second primary lesions
These efforts complement the site’s broader commitment to cancer prevention and public health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 6 therapeutic areas and 15 of 41 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Institut Gustave Roussy5active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Institut Gustave Roussy5trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Paris - Hôpital Cochin
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Seamless Phase 2a/2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa | Almirall S.A. | Phase II | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 41 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 3 | Unknown | 2020-11-03 | 2025-11-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.